Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 16.2005
- Book/Share 7.9596
- PB 5.3968
- Debt/Equity 1.082
- CurrentRatio 0.8186
- ROIC 0.1551
- MktCap 88559524037.991
- FreeCF/Share 3.1029
- PFCF 14.2029
- PE 15.4575
- Debt/Assets 0.2899
- DivYield 0.0297
- ROE 0.2979
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GSK | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | GSK | Barclays | Equal Weight | Underweight | -- | -- | Jan. 6, 2026 |
| Upgrade | GSK | BofA Securities | Underperform | Neutral | -- | -- | Nov. 25, 2025 |
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis.
Read More
5 Reasons GSK Looks Good
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Positive
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
Read More
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results …
Read More
Here's Why GSK (GSK) is a Strong Momentum Stock
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc leads the market, with Cervarix targeting HPV-linked conditions like cervical cancer. Advanced HPV vaccines and personalized immunization strategies are emerging trends. The report details market dynamics, historical data, and future growth projections. The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vaccination rates, and global immunization programs. GSK plc …
Read More
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
Published: April 30, 2025 by: Investopedia
Sentiment: Positive
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.
Read More
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
Read More
GSK (GSK) Q1 Earnings Surpass Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.
Read More
GSK jumps 4% as earnings beat boosts confidence
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidance. The FTSE 100 group reported core earnings per share of 44.9p, 10% ahead of consensus, thanks to stronger operating leverage and a robust margin of 33.7%.
Read More
GSK beats earnings forecasts despite weaker vaccine sales
Published: April 30, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) reported earnings ahead of expectations and kept full-year guidance intact, even though sales of vaccines softened. The FTSE 10-listed drugmaker reported a 6.1% fall in vaccine sales to £2.10 billion, which was almost in line with the $2.11 billion average City forecast.
Read More
GSK Sales, Profit Rise on Boost from Cancer Drugs
Published: April 30, 2025 by: WSJ
Sentiment: Positive
The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the year prior.
Read More
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
UK approves combination therapies of GSK's blood cancer drug Blenrep
Published: April 17, 2025 by: Reuters
Sentiment: Positive
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at least one other therapy previously.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc (GSK)
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141540&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
Published: April 07, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141513&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141095&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140947&wire=1 or contact Joseph E. Levi, Esq.
Read More
GSK Shareholders Have Opportunity to Lead GSK plc Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
Read More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)
Published: April 04, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022.
Read More
GSK plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=140894&wire=1 or contact Joseph E. Levi, Esq.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Luke Victor Miels
- Employees 68629